Natriuretic peptide measurement detected left ventricular dysfunction in pacemaker patients who might otherwise be missed, supporting BNP screening in this cardiac device population.
Key findingNatriuretic peptide levels identified LV dysfunction and comorbidities in pacemaker patients, supporting BNP measurement for detecting subclinical hea
What the researchers found
Natriuretic peptide levels identified LV dysfunction and comorbidities in pacemaker patients, supporting BNP measurement for detecting subclinical heart failure in cardiac device populations.
Why it matters
Advances understanding in natriuretic-peptides, cardiovascular, clinical-trials research.
How the study worked
cross-sectional study. Details in abstract.
What this study cannot tell us
See abstract for study-specific limitations.
How to read the evidence
moderate evidence from cross-sectional study.
When this study was published
Published in 2004.
The bigger picture
Contributes to the growing body of evidence in peptide research.
Questions still open
- Further research needed to confirm and extend findings.
- Clinical translation potential to be evaluated.
Common questions
What was studied?
What was found?
Read the original research
Natriuretic peptides and the prevalence of congestive heart failure in patients with pacemakers.
European journal of clinical investigation, 34(12), 811-7
Citation
Gwechenberger, M; Huelsmann, M; Graf, S; Berger, R; Bonderman, D; Stanek, B; Rauscha, F; Pacher, R. (2004). Natriuretic peptides and the prevalence of congestive heart failure in patients with pacemakers.. European journal of clinical investigation, 34(12), 811-7.